Amicus Therapeutics, Inc. To Trim 14 Percent Of Workforce, Restructures As GlaxoSmithKline Revises Pact
Published: Nov 22, 2013
Amicus is axing jobs but others are hiring too! Check it out! (Isn't it tempting?)
Amicus Therapeutics and GSK Announce Revised Fabry Agreement
Amicus Therapeutics hinted earlier this year that some dealmaking was on the way following a regulatory setback for its lead drug that crippled its market value. Today was apparently the day it had in mind.
Cranbury, NJ-based Amicus (NASDAQ: FOLD) today announced a series of strategic moves, including an acquisition, an equity investment, and a significant staff layoff. Essentially, these moves leave Amicus a leaner company with a new drug that is in preclinical development, but still one that has yet to successfully push a drug through a pivotal study and get it to market, and is a ways away from doing so.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)
Amicus Therapeutics and GSK Announce Revised Fabry Agreement
Amicus Therapeutics hinted earlier this year that some dealmaking was on the way following a regulatory setback for its lead drug that crippled its market value. Today was apparently the day it had in mind.
Cranbury, NJ-based Amicus (NASDAQ: FOLD) today announced a series of strategic moves, including an acquisition, an equity investment, and a significant staff layoff. Essentially, these moves leave Amicus a leaner company with a new drug that is in preclinical development, but still one that has yet to successfully push a drug through a pivotal study and get it to market, and is a ways away from doing so.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)